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Abstract: The structural features of MUC1-like glycopeptides
bearing the Tn antigen (a-O-GalNAc-Ser/Thr) in complex
with an anti MUC-1 antibody are reported at atomic resolu-
tion. For the a-O-GalNAc-Ser derivative, the glycosidic link-
age adopts a high-energy conformation, barely populated in
the free state. This unusual structure (also observed in an a-S-
GalNAc-Cys mimic) is stabilized by hydrogen bonds between
the peptidic fragment and the sugar. The selection of a partic-
ular peptide structure by the antibody is thus propagated to the
carbohydrate through carbohydrate/peptide contacts, which
force a change in the orientation of the sugar moiety. This
seems to be unfeasible in the a-O-GalNAc-Thr glycopeptide
owing to the more limited flexibility of the side chain imposed
by the methyl group. Our data demonstrate the non-equiv-
alence of Ser and Thr O-glycosylation points in molecular
recognition processes. These features provide insight into the
occurrence in nature of the APDTRP epitope for anti-MUC1
antibodies.
The Tn antigen (a-O-GalNAc-Ser/Thr) is one of the most
specific human tumor-associated structures.[1] This entity,
which is also implicated in HIV infection,[2] is expressed in
approximately 90% of carcinomas, and a direct correlation
between the aggressiveness of the carcinoma and the
occurrence of the antigen has been observed.[3] Consequently,
the Tn antigen has found widespread use as biomarker and as
a potential therapeutic target against cancer.[1,4–7] Structural
analysis of Tn antigen bound to its biological targets is thus of
great significance for elucidating the mechanism of recogni-
tion, as well as for engineering novel antibodies and
[*] Dr. N. Martnez-Sez,[+] Dr. D. Madariaga, I. CompaÇün,
Dr. V. J. Somovilla, Dr. A. Avenoza, Dr. J. H. Busto,
Dr. J. M. Peregrina, Dr. F. Corzana
Departamento de Qumica, Universidad de La Rioja




Dr. N. Martnez-Sez,[+] Dr. V. J. Somovilla, M. Salvadü,
Dr. G. J. L. Bernardes
Department of Chemistry, University of Cambridge
Lensfield Road, Cambridge CB2 1EW (UK)
J. Castro-Lüpez,[+] J. Valero-Gonzlez,[+] Dr. R. Hurtado-Guerrero
Institute of Biocomputation and Physics of Complex Systems (BIFI)
University of Zaragoza, BIFI-IQFR (CSIC) Joint Unit
Edificio I+D, 50018 Zaragoza (Spain)
and
Fundaciün ARAID
Edificio Pignatelli 36, Zaragoza (Spain)
E-mail: rhurtado@bifi.es
M. Salvadü
Departament de Qumica Analtica i Qumica Orgnica, Universitat
Rovira i Virgili, C/Marcell Domingo s/n, 43007 Tarragona (Spain)
Dr. J. L. Asensio
Instituto de Qumica Orgnica General, IQOG-CSIC
Juan de la Cierva 3, 28006 Madrid (Spain)
Dr. J. Jim¦nez-Barbero
Structural Biology Unit, CIC bioGUNE
Parque Tecnolügico de Bizkaia Building 801 A, 48160 Derio (Spain)
and
IKERBASQUE, Basque Foundation for Science
48011 Bilbao (Spain)
and
Department of Chemical and Physical Biology
Centro de Investigaciones Biolügicas, CSIC
Ramiro de Maeztu 9, 28040 Madrid (Spain)
Dr. G. J. L. Bernardes
Instituto de Medicina Molecular
Faculdade de Medicina da Universidade de Lisboa
1649-028 Lisboa (Portugal)
[+] These authors contributed equally to this work.
[**] We thank the Ministerio de Economa y Competitividad/FEDER
(project CTQ2012-36365, CTQ2012-32065, BFU2010-19504,
CTQ2013-44367-C2-2-P, UNLR13-4E-1931 and grant I.C.) and DGA
(B89) for financial support. N.M.-S. and D.M. thank Universidad de
La Rioja for FPI grants. We thank Katherine Stott (Department of
Biochemistry, Cambridge University) for technical help with the BLI
experiments. G.J.L.B. thanks financial support from the EPSRC.
G.J.L.B. is a Royal Society University Research Fellow. M.S. thanks
the Generalitat de Catalunya and Universitat Rovira i Virgili for
financial support. We thank synchrotron radiation sources DLS
(Oxford), and in particular beamlines I04 (experiment number
MX8035-26) and I02 (experiment number MX10121-2), respectively.
The research leading to these results has also received funding from
the FP7 (2007-2013) under BIOSTRUCTX-7687. We also thank
CESGA for computer facilities.
Supporting information for this article is available on the WWW
under http://dx.doi.org/10.1002/anie.201502813.
Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co.
KGaA. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and




9830 Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2015, 54, 9830 –9834
biosensors. In general, the Tn
antigen is referred to as N-
acetylgalactosamine
(GalNAc) a-O-linked to
serine (Ser) or threonine
(Thr), without specifying
which of the two amino acids
the GalNAc is linked to. How-
ever, we and others have
observed the existence of
subtly different conforma-
tional behaviors in solution
of the basic Ser- and Thr-
containing structures.[8–14]
Herein, we present
a detailed analysis of the inter-
action of these two Tn deter-
minants, as MUC1 glycopep-
tides, to an anti-MUC1 anti-
body. MUC1 is a heavily O-
glycosylated membrane glyco-
protein consisting of tandem
repeats of 20 amino acids
(AHGVTSAPDTRPAPG-
STAPP), with five possible
glycosylation sites.[15, 16] This
protein is overexpressed and
partially glycosylated in cancer cells. Consequently, some
peptide fragments that are masked in healthy cells, such as
APDTRP and their glycosylated analogues, are now acces-
sible and can interact with the immune system. Although the
observed enhancement of antibody affinity has been attrib-
uted to conformational changes induced by the glycan in the
peptide backbone,[17–20] the molecular basis for this observa-
tion remains unclear.
To our knowledge, the only reported crystal structure of
a complex between an antibody and a GalNAc-containing
glycopeptide is unrelated to mucins.[21] In addition, the X-ray
structure of a model anti-MUC1 antibody (SM3) in complex
with a mucin is limited to a naked peptide.[22] Moreover, an
NMR study on this peptide and its corresponding GalNAc-
glycopeptide bound to SM3 led to the hypothesis that the
sugar residue fixes the bioactive conformation of the peptide
fragment and interacts via theN-acetyl group with the surface
of the antibody.[23] However, no detailed information on the
intermolecular interactions could be deduced from this
ligand-based NMR analysis.
A detailed analysis of the interactions between the SM3
antibody and two synthetic glycopeptides bearing the a-O-
GalNAc-Thr and a-O-GalNAc-Ser antigens (m1* and m2*
respectively; Figure 1) is presented herein. These molecules
include the tandem repeat sequence of MUC1. The SM3
antibody was selected because its epitope recognition mode is
similar to that of other anti-MUC1 antibodies,[24] which
expands the scope of these results, and also because of its
potential for use in the early diagnosis and treatment of breast
cancer.[22]
The influence of the chemical nature of the underlying
amino acid, as well as the GalNAcylation, on antibody
binding affinity was first evaluated. For this purpose, the
related naked peptides (m1 and m2, respectively; Figure 1)
were also synthesized and tested. The KD constants for the
MUC1 variants with the scFv-SM3 antibody were experi-
mentally determined through bio-layer interferometry (BLI)
experiments. The higher affinity (around 3-fold) of SM3 for
glycosylated m1* compared the naked peptide m1 was
confirmed by these tests[24] (Figure 1). Furthermore, the Ser-
containing compounds showed significantly lower affinity,
thus highlighting the differences between the two Tn antigens.
These results were corroborated by ELISA tests (see the
Supporting Information).
To explain these results at the atomic level, a scFv-SM3
antibody was produced and purified. High quality crystals of
the SM3:1, SM3:1*, and SM3:2* complexes were obtained,
where 1, 1* and 2* are simplified models ofm1,m1* andm2*,
respectively (Figure 2a, PDB IDs 5a2j, 5a2k, and 5a2i). These
compounds include the peptide fragment that represents the
minimal epitope recognized by most anti-MUC1 antibod-
ies.[24]
The obtained crystals enabled solution of the structures at
high resolution (< 2.0 è, see the Supporting Information).
Crystallographic analysis revealed that the surface groove of
the recombinant SM3 antibody nicely fits all of the peptide
residues in the three studied complexes (Figure 2b), inde-
pendent of the presence of the sugar moiety. Moreover, the
overall conformation of the peptide fragment of the different
simplified MUC1 variants is nearly identical and is similar to
that found in the crystal structure reported for the naked
peptide[22] (Figure 2c and Figure 3).
Therefore, the presence of the GalNAc moiety, regardless
of the attached amino acid (Ser or Thr), does not significantly
Figure 1. The MUC1-like peptides and glycopeptides studied in this work (upper panel). Bio-layer
interferometry (BLI) curves and fit obtained for glycopeptide m1* and scFv-SM3, together with the KD
constants derived from BLI experiments for all of the MUC1-related compounds (lower panel).
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affect the conformation of the peptide backbone in the SM3-
bound state. In fact, the antibody–antigen pairs display the
same pattern of interactions with each of the three substrates
(1, 1* and 2*) and with the reported peptide[22] (Figure 3). The
stabilizing contacts in these complexes involve several hydro-
gen bonds, some of themmediated by water molecules, as well
as several stacking interactions (Figure 3 and the Supporting
Information). Pro2 stacks with Trp91L, Trp96L, and Tyr32L,
while the side-chains of Asp3 and Arg5 are engaged in
hydrophobic contacts with Trp33H and Tyr32H, respectively.
Additionally, in compounds 1* and 2*, the NH group of Ala1
and the carbonyl group of Thr4/Ser4 are involved in hydrogen
bonds with Tyr32L and Gln97H, respectively. The 3D
presentation of the side chain of Arg5 in glycopeptide 2*
(Figure 2c) differs slightly from that found for the other
analogues. As a result, there is no hydrogen bond between the
side chain of Arg5 and the carbonyl group of Asn31H. This
interaction, among other factors (see below), may be at the
cause of the low affinity of SM3 for 2*.
Interestingly, the major difference between glycopeptides
1* and 2* bound to SM3 resides in the geometry of the
glycosidic linkage (Figure 4a). In fact, in the SM3:1* complex,
this linkage adopts the expected exo-anomeric/syn conforma-
tion, with f andy values of around 638 and 918, respectively.[9]
This conformation is similar to that found for a non-related
MUC1 glycopeptide bound to 237-mAb[21] (Figure 4b) and
that exhibited for 1* bound to a model lectin (Soybean
agglutinin).[25] This geometry allows the formation of an
intermolecular hydrogen bond between the hydroxymethyl
group of GalNAc and the side chain of Tyr32L on the SM3
antibody. Moreover, the N-acetyl group of the sugar stacks
with the aromatic ring of Trp33H, thus providing the impetus
for the observed selectivity of SM3 for GalNAc-containing
antigens. This interaction is compatible with the previous
solution NMR data.[23] By contrast, the GalNAc unit of
compound 2* establishes only weak water-mediated hydrogen
bonds with the antibody (see the Supporting Information).
Figure 2. a) Simplified MUC1 variants used for crystallization. b) Sur-
face representation of SM3 in complex with 1*. The antigen is shown
as a stick model with carbon atoms in green. c) Superposition of the
peptide backbone of compounds 1, 1*, 2*, and the SAPDTRPAP
peptide[22] in complex with SM3.
Figure 3. Key binding interactions of peptide 1 (a), glycopeptide 1* (b),
and glycopeptide 2* (c) with SM3 mAb, as observed in the X-ray
crystal structures. Peptide and glycopeptide carbon atoms are shown
in green. GalNAc carbon atoms are shown in cyan. Carbon atoms of
key residues of SM3 are colored yellow. Blue dashed lines indicate
interactions between GalNAc and SM3 surface, and pink dashed lines
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The glycosidic linkage shows a high-energy conformation,
with a y value of around ¢978 (Figure 4a,c). This conforma-
tion is barely populated for the a-O-GalNAc-Ser motif in
solution. In fact, the conformational analysis performed on
glycopeptides 1* and 2* in the free state in water by means of
NMR experiments and Molecular Dynamics (MD) simula-
tions with time-averaged restraints[9] indicates that compound
2* displays this conformation with a population approxi-
mately 20% (see the Supporting Information). As previously
observed by us,[8, 9] while in compound 1*, the glycosidic
linkage adopts mainly the typical eclipsed conformation, in
variant 2* it prefers to adopt the alternate conformation.
According to the X-ray structure, the unusual conformation
of the glycosidic linkage in compound 2* bound to the
antibody is stabilized by two intramolecular hydrogen bonds
with the peptide chain (Figure 5). The GalNAc endocyclic
oxygen O5 engages in a hydrogen bond with the NH group of
the attached Ser and the O6 interacts with the side chain of
Asp3. To our knowledge, this geometry of the glycosidic
linkage has not been previously observed for protein-bound
Tn-containing peptides. It is important to note that the quality
of the SM3:2* structure was lower and that the B-factor for 2*
was higher compared to the other structures, which may
indicate some degree of flexibility.
MD simulations performed for the SM3:2* complex
corroborated this flexibility in the bound state. The X-ray
conformation was retained only for the first 4 ns of the
trajectory (see the Supporting Information). Then, the
glycosidic linkage exhibits the typical parallel orientation
found for this compound in the free state.[8] To reinforce the
significance of the b-methyl group of the threonine residue for
the conformation of the glycosidic linkage, and to corroborate
the exceptional 3D conformation of glycopeptide 2* in the
complex with the antibody, we solved the structure of the
cysteine analogue in complex with scFv-SM3 (compound 3*
in Figure 2, PDB ID: 5a2L). Notably, the GalNAc unit and
the peptide backbone adopt an almost identical spatial
conformation in glycopeptides 2* and 3*, with the main
difference being the conformation of the side chain of Arg5
(Figure 5). Therefore, the selection of a particular peptide
structure by the antibody is somehow propagated to the
carbohydrate through specific carbohydrate/peptide contacts,
thereby forcing a drastic change in the orientation of the sugar
moiety. This situation is not possible in the Thr-containing
derivative owing to the limited conformational freedom of its
side chain imposed by the methyl group (Figure 5). As
a result, the GalNAc unit adopts a completely different
presentation when linked to the threonine residue, with most
of the hydroxy groups exposed and able to interact with the
corresponding partners of the immune system.
In conclusion, we have uncovered, at the atomic level, the
reasons why Ser- and Thr-linked glycopeptides bind differ-
ently to SM3. We have provided experimental evidences for
distinct presentations of the Tn-carrying serine (a-GalNAc-
Ser) and threonine (a-GalNAc-Thr) antigens when bound to
SM3. The reasons for the observed limited enhancement in
SM3 affinity in 1* versus 1 can be attributed to the weak
hydrogen bond between O6 and Tyr32L, and a hydrophobic
contact between the methyl group of the GalNAc unit and
Trp33H. These findings emphasize the differences between
these two Tn antigens in the context of recognition by anti-
MUC1 antibodies and may have important implications for
the design of novel antibodies and biosensors. In addition, our
findings may provide insight into the occurrence in nature of
the APDTRP epitope for anti-MUC1 antibodies.
Figure 4. a) Distribution of f/y torsional angles found for a-O-
GalNAc-Ser and a-O-GalNAc-Thr in water,[8, 9] together with the geo-
metries found in X-ray structures for these determinants when bound
to some biological targets.[21, 25–28] Newman projections of Cb–O1 bond
are shown. b) Superposition of the Tn antigen moiety a-O-GalNAc-Thr
bound to SM3 (in green) and 237-mAb (in yellow; mAb=monoclonal
antibody).[21] c) Superposition of the Tn antigen moiety a-O-GalNAc-
Ser bound to SM3 mAb (in green) and to HPA lectin (in yellow).[27]
Figure 5. Conformation of glycopeptides 2* (in green and cyan) and 3*
(in brown) in complex with scFv-SM3 antibody, together with the
geometry of the glycosidic linkage and the hydrogen bonds established
with the peptide fragment.
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